v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenue $ 1,150 $ 2,457
Cost of sales 146 292
Gross profit 1,005 2,165
Operating expenses:        
Research and development 319,744 330,772 949,388 877,674
Clinical development 60,941 33,972 141,684 78,241
General and administrative 596,476 161,549 1,298,409 591,155
Total operating expenses 977,161 526,293 2,389,481 1,547,070
Loss from operations (976,156) (526,293) (2,387,316) (1,547,070)
Other income (expense):        
Interest income 3 19 850 24
Interest expense (889,091) (135,359) (2,435,941) (363,828)
Gain on extinguishment of debt 212,258 239,200
Fair value adjustments on convertible notes payable (3,053,914) (852,161) (1,866,922) 924,099
Net loss before provision for income taxes (4,919,158) (1,513,794) (6,477,071) (747,575)
Income tax expense 300 2,459 1,950
Net loss $ (4,919,458) $ (1,513,794) $ (6,479,530) $ (749,525)
Net loss per common share, basic and diluted $ (1.17) $ (0.57) $ (2.03) $ (0.28)
Weighted average common shares outstanding 4,203,781 2,675,054 3,194,765 2,674,924

Source